Skip to main content
Wiley Open Access Collection logoLink to Wiley Open Access Collection
editorial
. 2026 Jun 2;67(7):3829–3830. doi: 10.1002/epi.70305

Interview with Jeffrey A. Mensah, recipient of the 2026 Epilepsia Prize for basic science research

Fernando Cendes 1,✉, Stéphane Auvin 2,3,4,5
PMCID: PMC13360905  PMID: 42227024

graphic file with name EPI-67-3829-g001.jpg

The 2026 Epilepsia Prize is awarded to the first author of the most outstanding original research article published in Epilepsia, selected from Volume 66 (2025). The 2026 Basic Science Research award recognizes “Development of a Preclinical Testing Platform for Clinically Relevant Therapy of Dravet Syndrome” by Jeffrey A. Mensah as work of exceptional scientific quality, impact, and relevance.

Jeffrey A. Mensah discusses the award‐winning research, its impact, and future directions.

PLEASE TELL US ABOUT YOURSELF, INCLUDING YOUR EDUCATION, TRAINING, AND CURRENT POSITION

I am Jeffrey Amoako Mensah from Ghana, West Africa. I earned my undergraduate degree in Biochemistry and my master's degree in pharmacology from the University of Ghana, followed by a PhD in Pharmacology and Toxicology from the University of Utah in the lab of Dr. Karen Wilcox. I am currently a postdoctoral trainee with Invent at Seattle Children's Postdoctoral Scholars Program in the lab of Dr. Franck Kalume. Outside of research, I enjoy playing soccer and video games.

HOW DID YOU BECOME INTERESTED IN CONDUCTING RESEARCH IN THIS FIELD?

My research interest in epilepsy started back in high school. My favorite chemistry teacher had seizures in class one day, and that event really sparked my curiosity and search for an understanding of seizures and epilepsy. At that young age, I asked myself: What can I do as a scientist to help people with this condition? Thus, I joined a neuropharmacology lab during my master's degree, where I was first introduced to basic science research in epilepsy. The more I learned about the brain and epilepsy, the more I enjoyed it.

DESCRIBE THE QUESTION YOUR STUDY ADDRESSED AND HOW YOU APPROACHED IT

The objective of this study was to address the unmet need for effective therapies in drug‐resistant Dravet syndrome by developing a preclinical platform with improved translational relevance. Specifically, we sought to determine whether a clinically representative polytherapy regimen could be modeled in an etiologically relevant system to better predict therapeutic efficacy.

To achieve this, we utilized the Scn1aA1783V/WT mouse model of Dravet syndrome and implemented a subchronic (14‐day) dosing paradigm using clobazam and valproic acid, with stiripentol as an add‐on therapy. Drug dosing was guided by pharmacokinetic analyses to ensure plasma concentrations comparable to those observed in patients. Treatment efficacy was evaluated using both the hyperthermia‐induced seizure assay and continuous video‐electroencephalographic (video‐EEG) monitoring of spontaneous seizures. This integrated design enabled us to establish a clinically relevant and predictive preclinical framework for evaluating combination therapies and facilitating the discovery of novel antiseizure treatments.

WHAT WERE THE RESULTS AND HOW DO YOU INTERPRET YOUR FINDINGS?

Our study showed that adding stiripentol to the standard combination of clobazam and valproic acid significantly improved seizure control in a preclinical model of Dravet syndrome. Specifically, the triple therapy:

  1. Increased the temperature threshold for hyperthermia‐induced seizures, indicating protection against febrile seizures; and

  2. Significantly reduced spontaneous seizure frequency as measured by continuous video‐EEG monitoring.

Additionally, a subset of animals achieved complete seizure freedom, which is particularly notable in a drug‐resistant epilepsy model. Importantly, all drugs reached clinically relevant plasma concentrations, supporting its translational relevance.

These findings demonstrate that a clinically relevant polytherapy approach can be successfully modeled in a preclinical system and can overcome pharmacoresistance observed with standard treatments alone. The enhanced efficacy of the triple therapy supports its clinical use and validates the predictive value of this model. More broadly, this study shows that incorporating pharmacokinetic‐guided dosing, chronic treatment paradigms, and multiple seizure endpoints creates a more reliable and translatable platform for drug discovery. This approach increases confidence that therapies identified in this model are more likely to succeed in clinical settings. Ultimately, our work establishes a framework for testing new investigational therapies in combination with standard‐of‐care treatments, which is critical for improving outcomes in patients with drug‐resistant Dravet syndrome.

WHAT ARE THE NEXT STEPS FOR YOUR RESEARCH, AND WHAT ARE YOUR BROADER CAREER GOALS?

I am currently a postdoctoral trainee in the lab of Dr. Franck Kalume, working to advance the development of a novel gene therapy for Leigh syndrome. My career goals include becoming an independent researcher with a lab that plays a leading role in advancing understanding of the molecular and genetic mechanisms that drive childhood epilepsy and related conditions, with the goal of making discoveries that lead to improved treatments for affected children and adults.

WHAT DOES RECEIVING THE EPILEPSIA PRIZE MEAN TO YOU, YOUR TEAM, AND YOUR FUTURE WORK?

It is such a profound honor for me and my coauthors to receive the Epilepsia Prize. This award shines a global spotlight on the innovative and outstanding research being conducted in the lab of my PhD mentor, Dr. Karen Wilcox, and the Contract Site of the Epilepsy Therapy Screening Program at the University of Utah. Receiving this award at such an early stage of my career fills me with immense pride, and I am very grateful.

ACKNOWLEDGMENTS

The authors thank Laurie Beninsig for the editorial assistance.


Articles from Epilepsia are provided here courtesy of Wiley

RESOURCES